Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer

被引：2

作者：

Suzuki, Motoyuki ^{[1
]}

Takenaka, Yukinori ^{[1
]}

Kishikawa, Toshihiro ^{[2
]}

Yamamoto, Yoshifumi ^{[1
]}

Hanamoto, Atsushi ^{[1
]}

Tomiyama, Yoichiro ^{[2
]}

Fukusumi, Takahito ^{[1
]}

Michiba, Takahiro ^{[1
]}

Takemoto, Norihiko ^{[1
]}

Nakahara, Susumu ^{[1
]}

Inohara, Hidenori ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan

[2] Osaka Rosai Hosp, Dept Otorhinolaryngol Head & Neck Surg, Sakai, Osaka, Japan

来源：

ANTICANCER RESEARCH | 2021年 / 41卷 / 04期

关键词：

Drug therapy; cisplatin; docetaxel; cetuximab; granulocyte colony-stimulating factor; squamous cell carcinoma of the head and neck;

D O I：

10.21873/anticanres.14973

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To retrospectively evaluate the efficacy and safety of modified TPEx (docetaxel 60 mg/m(2) on day 1, cisplatin 60 mg/m(2) on day 1, and weekly cetuximab 250 mg/m(2) with loading dose of 400 mg/m(2)) followed by maintenance cetuximab as first-line treatment for inoperable recurrent and/or metastatic squamous cell carcinoma of the head and neck. Patients and Methods: We analyzed 22 Japanese patients receiving modified TPEx every 21 days for four cycles with or without prophylactic granulocyte colonystimulating factor (G-CSF). Results: The best overall response rate was 55% [95% confidence interval (CI)=35-73]. The median progression-free survival and overall survival were 8.9 months (95%CI=3.9-10.2) and 14.3 months (95%CI=10.1-28.2), respectively. Without prophylactic G-CSF, Grade 3/4 neutropenia and febrile neutropenia was common (94% versus 20%; p=0.003 and 41% versus 0%; p=0.11, respectively). Conclusion: The modified TPEx is effective, while prophylactic G-CSF is essential.

引用

页码：2045 / 2051

页数：7

共 12 条

[1] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[2] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[3] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[4] Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study [J].

Guigay, J. ;

Fayette, J. ;

Dillies, A. F. ;

Sire, C. ;

Kerger, J. N. ;

Tennevet, I. ;

Machiels, J. P. ;

Zanetta, S. ;

Pointreau, Y. ;

Bozec Le Moal, L. ;

Henry, S. ;

Schilf, A. ;

Bourhis, J. .

ANNALS OF ONCOLOGY, 2015, 26 (09) :1941-1947

[5]

Guigay J, 2020, J CLIN ONCOL, V38

[6] TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). [J].

Guigay, Joel ;

Fayette, Jerome ;

Mesia, Ricard ;

Lafond, Cedrik ;

Saada-Bouzid, Esma ;

Geoffrois, Lionnel ;

Martin, Laurent ;

Cupissol, Didier ;

Capitain, Olivier ;

Castanie, Helene ;

Vansteene, Damien ;

Schafhausen, Philippe ;

Arvis, Catherine Dubos ;

Even, Caroline ;

Sire, Christian ;

Delhommeau, Melissa ;

Michel, Cecile ;

Bourhis, Jean ;

Keilholz, Ulrich ;

Auperin, Anne .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[7] Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial [J].

Guo, Ye ;

Shi, Mei ;

Yang, Ankui ;

Feng, Jifeng ;

Zhu, Xiaodong ;

Choi, Young-Jin ;

Hu, Guoqin ;

Pan, Jianji ;

Hu, Chunhong ;

Luo, Rongcheng ;

Zhang, Yiping ;

Zhou, Liang ;

Cheng, Ying ;

Luepfert, Christian ;

Cai, Junliang ;

Shi, yuankai .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (08) :1081-1087

[8] Phase 2 Study of Docetaxel, Cisplatin, and Concurrent Radiation for Technically Resectable Stage III-IV Squamous Cell Carcinoma of the Head and Neck [J].

Inohara, Hidenori ;

Takenaka, Yukinori ;

Yoshii, Tadashi ;

Nakahara, Susumu ;

Yamamoto, Yoshifumi ;

Tomiyama, Yoichiro ;

Seo, Yuji ;

Isohashi, Fumiaki ;

Suzuki, Osamu ;

Yoshioka, Yasuo ;

Sumida, Iori ;

Ogawa, Kazuhiko .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (05) :934-941

[9] Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population [J].

Maruyama, Hiromi ;

Yasui, Toshimichi ;

Ishikawa-Fujiwara, Tomoko ;

Morii, Eiichi ;

Yamamoto, Yoshifumi ;

Yoshii, Tadashi ;

Takenaka, Yukinori ;

Nakahara, Susumu ;

Todo, Takeshi ;

Hongyo, Tadashi ;

Inohara, Hidenori .

CANCER SCIENCE, 2014, 105 (04) :409-417

[10] Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: The Memphis experience [J].

Robbins, KT ;

Kumar, P ;

Regine, WF ;

Wong, FSH ;

Weir, AB ;

Flick, P ;

Kun, LE ;

Palmer, R ;

Murray, T ;

Fontanesi, J ;

Ferguson, R ;

Thomas, R ;

Hartsell, W ;

Paig, CU ;

Salazar, G ;

Norfleet, L ;

Hanchett, CB ;

Harrington, V ;

Niell, HB .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (02) :263-271

← 1 2 →